4.3 Article

Potential New Therapeutic Targets for Pathological Pruritus

Journal

BIOLOGICAL & PHARMACEUTICAL BULLETIN
Volume 36, Issue 8, Pages 1228-1234

Publisher

PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/bpb.b13-00343

Keywords

pruritic disease; itch mediator; keratinocyte; primary sensory neuron; dorsal horn neuron; itch inhibitory system

Funding

  1. Grants-in-Aid for Scientific Research [23390153] Funding Source: KAKEN

Ask authors/readers for more resources

Very few approved medications are indicated for the treatment of pruritus, and drug development for pruritic diseases is awaited. During the past two decades, progress has been made in understanding the molecular basis of the physiology and pathophysiology of pruritus. Newly identified potential targets for pathological pruritus include receptors (histamine H-4 receptor, leukotriene B-4 receptors, interleukin-31 receptor A, bombesin BB2 receptor, toll-like receptor 3, alpha-adrenoceptor, and opioid, mu- and kappa-receptors), channels (transient receptor potential (TRP) V3 and TRPA1 channels), and enzymes (histidine decarboxylase, sphingomyelin glucosylceramide deacylase, 5-lipoxygenase, leukotriene A(4) hydrolase, and autotaxin). The development of specific, effective blockers and agonists/antagonists of these targets is awaited.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available